石藥集團(01093.HK):“多索茶礆注射液”獲藥品註冊批件
格隆匯5月18日丨石藥集團(01093.HK)發佈公吿,公司附屬公司石藥集團歐意藥業有限公司開發的“多索茶礆注射液(10ml:0.1g)”已獲得中國國家藥品監督管理局頒發的藥品註冊批件,並視同通過仿製藥質量和療效一致性評價。
多索茶礆是甲基黃嘌呤的衍生物,通過抑制平滑肌細胞內的磷酸二酯酶,鬆弛支氣管平滑肌,從而達到抑制哮喘的作用。作為一種支氣管擴張劑,該產品用於治療支氣管哮喘、慢性喘息性支氣管炎及其他支氣管痙攣引起的呼吸困難。該產品的獲批將進一步豐富集團於呼吸系統疾病領域的產品線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.